LYEL News and Press, Lyell Immunopharma Inc. From 12/02/21

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that Dr. Rick Klausner is resuming his role as Chair of Lye...

Lyell Immunopharma (NASDAQ:LYEL): Q3 Net Loss of $48.87M Revenue of $2.75M (+157.0% Y/Y) beats by $0.45M. Press Release For further details see: Lyell Immunopharma EPS beats by $49.14, beats on revenue

Cash and investments of $936.4 million as of September 30, 2021 supports advancing multi-modality cell therapy pipeline SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the ...

Healthcare stocks in the S&P 500 edged past the ~0.6% loss in the broader index over the week to end ~0.2% lower, becoming the fourth best performing sector. Among stocks with more than $300M market cap and over 100K average daily volume over the past five sessions, BELLUS Health (NA...

Gainers: Itamar (NASDAQ:ITMR) +46%. Aterian (NASDAQ:ATER) +40%. aTyr Pharma (NASDAQ:LIFE) +37%. iRhythm Technology (NASDAQ:IRTC) +34%. BELLUS (NASDAQ:BLU) +26%. Leap Therapeutics  (NASDAQ:LPTX) +30%. REGENXBIO (NASDAQ:RGNX) +25%. Datasea (NASDAQ:DTSS) +20%. Uranium Royalty (NASDAQ:UROY) ...

Gainers: Itamar Medical ITMR +45%, aTyr Pharma LIFE +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO RGNX +20%, Leap Therapeutics LPTX +15%. Losers: MiMedx MDXG -61%, Silverback Therapeutics (NASDAQ:SBTX) -24%, Dynavax T...

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participat...

Lyell Immunopharma Inc. (NASDAQ:LYEL) traded at a new 52-week high today of $19.75. This new high was reached on approximately average trading volume as 221,000 shares traded hands, while the average 30-day volume is approximately 201,000 shares. Lyell Immunopharma Inc is a T cell reprog...

Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials Cash, cash equivalents and marketable securities of $974.8 million as of June 30, 2021 includes $391.8 million in net proceeds from initial public offering SOUTH SA...

Lyell Immunopharma Inc. (NASDAQ:LYEL) traded at a new 52-week low today of $13.82. This new low was reached on below average trading volume as 221,000 shares traded hands, while the average 30-day volume is approximately 595,000 shares. Lyell Immunopharma Inc. share prices have moved bet...